| P50 | author | Ellen M Ginzler | Q91640182 |
| P2093 | author name string | José Luis Andréu Sánchez | |
| | Lucía Silva Fernández | |
| P2860 | cites work | Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis | Q21195423 |
| | Exploring new territory: considering the future | Q28222277 |
| | Exploring new territory: the move towards individualised treatment | Q28222278 |
| | Cardiovascular risk factors and the long-term outcome of lupus nephritis | Q31846096 |
| | Treatment of proliferative lupus nephritis--a critical approach | Q33261680 |
| | Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 |
| | High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus | Q33366075 |
| | Intravenous immunoglobulin therapy and systemic lupus erythematosus | Q33369794 |
| | Epidemiology and estimated population burden of selected autoimmune diseases in the United States | Q33500191 |
| | Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature | Q33906791 |
| | Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus | Q33915449 |
| | Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 |
| | Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease | Q34555048 |
| | Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study | Q34897189 |
| | Treatment of severe proliferative lupus nephritis: the current state | Q35201234 |
| | EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis | Q35554126 |
| | Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials | Q35642238 |
| | Intravenous immunoglobulin and the kidney--a two-edged sword | Q35988937 |
| | Newer therapeutic approaches for systemic lupus erythematosus | Q36142486 |
| | Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus | Q36375753 |
| | Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus | Q36408007 |
| | Therapeutic options for resistant lupus nephritis | Q36555182 |
| | Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo | Q38349898 |
| | Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies | Q40646509 |
| | Intravenous immunoglobulin treatment of lupus nephritis | Q40765749 |
| | Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). | Q42638034 |
| | Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study | Q42662294 |
| | B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. | Q42669194 |
| | Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. | Q42956224 |
| | Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens | Q43691810 |
| | Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 |
| | Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. | Q43711419 |
| | The safety and efficacy of MMF in lupus nephritis: a pilot study | Q43777987 |
| | Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 |
| | Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents | Q44087206 |
| | Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. | Q44124868 |
| | An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 |
| | LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study | Q44305349 |
| | Lupus nephritis: treatment with mycophenolate mofetil | Q44764370 |
| | Sequential therapies for proliferative lupus nephritis | Q44785533 |
| | Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis | Q44826001 |
| | Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis | Q45034884 |
| | Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus | Q45088819 |
| | Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study | Q45099936 |
| | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial | Q45184210 |
| | Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. | Q45251915 |
| | Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. | Q46467090 |
| | Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy | Q46622469 |
| | Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis | Q46723567 |
| | Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis | Q46749401 |
| | Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 |
| | Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria | Q46903227 |
| | Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. | Q53920423 |
| | Long-term treatment of lupus nephritis with cyclosporin A. | Q53938948 |
| | Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. | Q54145043 |
| | Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. | Q54267030 |
| | A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years | Q57753805 |
| | The classification of glomerulonephritis in systemic lupus erythematosus revisited | Q58482164 |
| | Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients | Q66904183 |
| | Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only | Q67925070 |
| | A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group | Q68102206 |
| | Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine | Q68535020 |
| | Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 |
| | Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids | Q69414146 |
| | Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis | Q69498786 |
| | Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial | Q71553667 |
| | The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth | Q72158504 |
| | Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 |
| | Long-term treatment of systemic lupus erythematosus with cyclosporin A | Q73012997 |
| | Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group | Q73088409 |
| | Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide | Q73322168 |
| | Powerful morphometric indicator of prognosis in lupus nephritis | Q73484558 |
| | Lupus nephritis | Q73604873 |
| | Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease | Q77780588 |
| | Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis | Q78201135 |
| | A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade | Q79731944 |
| | Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial | Q79839545 |
| | Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis | Q79844545 |
| | Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis | Q80060133 |
| | LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus | Q80273016 |
| | Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study | Q80616378 |
| P433 | issue | 4 | |
| P304 | page(s) | 140-151 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Reumatología Clínica | Q26842348 |
| P1476 | title | [Treatment of lupus nephritis]. | |
| P478 | volume | 4 | |